IT1250366B - Materiale proteico ricombinante legante anticorpi contro il cigalomegavirus umano, reagenti diagnostici derivati da tale materialeproteico e plasmide ricombinante esprimente lo stesso. - Google Patents
Materiale proteico ricombinante legante anticorpi contro il cigalomegavirus umano, reagenti diagnostici derivati da tale materialeproteico e plasmide ricombinante esprimente lo stesso.Info
- Publication number
- IT1250366B IT1250366B ITTO911019A ITTO911019A IT1250366B IT 1250366 B IT1250366 B IT 1250366B IT TO911019 A ITTO911019 A IT TO911019A IT TO911019 A ITTO911019 A IT TO911019A IT 1250366 B IT1250366 B IT 1250366B
- Authority
- IT
- Italy
- Prior art keywords
- protein material
- recombinant
- protein
- same
- human cytomegalovirus
- Prior art date
Links
- 239000000463 material Substances 0.000 title abstract 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 title abstract 2
- 239000013612 plasmid Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Materiale proteico consistente in una proteina di fusione incorporante un determinante antigenico della proteina p52 del Citomegalovirus umano (HCMV), in particolare la sequenza carbossil-terminale degli ultimi 233 amminoacidi della proteina p52; il peptide è espresso da un plasmide ricombinante per introduzione dello stesso in E.coli e risulta fortemente reattivo verso IgM umane prodotte contro il Citomegalovirus durante la fase di infezione primaria; viene utilizzato, associato con antigeni tradizionali (virioni parzialmente purificati o cellule infette) e/o con altri peptidi sintetici o di fusione, come reagente antigenico in un kit ELISA per la ricerca di IgM HCMV- specifiche, oppure per la produzione di sieri policlonali monospecifici e/o di MaB anti-p52 del HCMV da utilizzare in kit diagnostici per il riconoscimento diretto dell'antigene virale.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITTO911019A IT1250366B (it) | 1991-12-23 | 1991-12-23 | Materiale proteico ricombinante legante anticorpi contro il cigalomegavirus umano, reagenti diagnostici derivati da tale materialeproteico e plasmide ricombinante esprimente lo stesso. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITTO911019A IT1250366B (it) | 1991-12-23 | 1991-12-23 | Materiale proteico ricombinante legante anticorpi contro il cigalomegavirus umano, reagenti diagnostici derivati da tale materialeproteico e plasmide ricombinante esprimente lo stesso. |
Publications (3)
Publication Number | Publication Date |
---|---|
ITTO911019A0 ITTO911019A0 (it) | 1991-12-23 |
ITTO911019A1 ITTO911019A1 (it) | 1993-06-24 |
IT1250366B true IT1250366B (it) | 1995-04-07 |
Family
ID=11409821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ITTO911019A IT1250366B (it) | 1991-12-23 | 1991-12-23 | Materiale proteico ricombinante legante anticorpi contro il cigalomegavirus umano, reagenti diagnostici derivati da tale materialeproteico e plasmide ricombinante esprimente lo stesso. |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT1250366B (it) |
-
1991
- 1991-12-23 IT ITTO911019A patent/IT1250366B/it active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
ITTO911019A0 (it) | 1991-12-23 |
ITTO911019A1 (it) | 1993-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2078694A1 (en) | Hepatitis b vaccine | |
Landini et al. | Large-scale screening of human sera with cytomegalovirus recombinant antigens | |
Rumpold et al. | The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1). | |
IT1266740B1 (it) | Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale | |
AU8849391A (en) | An augmented western blot format and immunoassay for detection of viral antibodies | |
Landini et al. | Human cytomegalovirus structural proteins: immune reaction against pp150 synthetic peptides | |
CA2057052A1 (en) | Enterically transmitted non-a/non-b hepatitis viral agent and characteristic epitopes thereof | |
AU1814692A (en) | Method for detecting bovine diarrhoea virus infection, nucleotide sequence encoding a protein induced by this virus infection and recombinant proteins and antigens relating thereto | |
CA2178057C (en) | Epstein-barr virus peptides and antibodies against these peptides | |
AU7211591A (en) | Immunologically active peptides or polypeptides from the parvovirus b19 | |
IT1250366B (it) | Materiale proteico ricombinante legante anticorpi contro il cigalomegavirus umano, reagenti diagnostici derivati da tale materialeproteico e plasmide ricombinante esprimente lo stesso. | |
AU4439993A (en) | HCV peptide antigens and method of determining HCV | |
US6197497B1 (en) | Immunoassay for herpes simplex virus | |
IT1250367B (it) | Materiale proteico legante anticorpi contro il citomegalovirus umano e reagenti diagnostici derivati da tale materiale proteico. | |
Maine et al. | The DNA-binding protein pUL57 of human cytomegalovirus: comparison of specific immunoglobulin M (IgM) reactivity with IgM reactivity to other major target antigens | |
ES2282847T3 (es) | Peptidos derivados del antigeno de la capside de vca-p18 del virus de epstein-barr y su uso. | |
EP1053248B1 (en) | Peptide structures and their use in diagnosis of herpes simplex virus type 2 | |
EP0754755A3 (de) | Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, diese enthaltende Testkits und Verfahren zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern | |
Modrow et al. | Identification of a protein encoded in the EB-viral open reading frame BMRF 2 | |
Nuebling et al. | Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insect cells | |
EP0985931A3 (en) | Recombinant antigen immunoassay for the diagnosis of syphilis | |
Welling-Wester et al. | Analogues of peptide 9–21 of glycoprotein D of herpes simplex virus and their binding to group VII monoclonal antibodies | |
Kühn et al. | The use of Western blot procedures in the analysis of herpes simplex virus proteins | |
Wolf et al. | Selection and production by genetechnological methods of medically relevant EBV-related antigens | |
Gan et al. | Distribution of Epstein‐Barr virus antigenic sites on the carboxyl terminal end of ribonucleotide reductase against nasopharyngeal carcinoma serum antibodies using an immunoabsorption method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
0001 | Granted | ||
TA | Fee payment date (situation as of event date), data collected since 19931001 |
Effective date: 19971218 |